Trial Profile
Potency of 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) at early time to predict the response of renal cell carcinoma to nivolumab.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 25 Jun 2018 New trial record
- 05 Jun 2018 Preliminary results (n=9) presented at the 54th Annual Meeting of the American Society of Clinical Oncology